Moderna (MRNA) Preferred Stock Liabilities (2017)

Moderna (MRNA) has reported Preferred Stock Liabilities for 1 consecutive years, with $1.2 billion the latest figure, recorded in Q4 2017.

• On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $1.2 billion in Q4 2017; TTM through Dec 2017 was $1.2 billion, a N/A change from a year earlier, with the FY2017 full-year figure at $1.2 billion, changed 0.0% from the prior year.
• Preferred Stock Liabilities was $1.2 billion for Q4 2017 at Moderna.
• Over five years, Preferred Stock Liabilities peaked at $1.2 billion in Q4 2017 and troughed at $1.2 billion in Q4 2017.